Alnylam Pharmaceuticals Inc.

01/14/2022 | Press release | Distributed by Public on 01/14/2022 06:04

Alnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the Société Francophone du Nerf Périphérique Annual Meeting